Acta Pharmacologica Sinica, Published online: 10 November 2026; doi:10.1038/s41401-026-01938-y A natural small molecule Hdj-15 coordinates the ER and lysosomes to induce ferroptosis by targeting TrxR1
Yue-qin Zhao, Fang-jiao Zhou, Xian-le Duan, Ai-ying Huang, Zheng-rui Xiang, Yu-han Zhao et al. A natural small molecule Hdj-15 coordinates the ER and lysosomes to induce ferroptosis by targeting TrxR1. // Acta Pharmacologica Sinica. – 2026. – DOI: 10.1038/s41401-026-01938-y. – URL: https://www.nature.com/articles/s41401-026-01938-y
Yue-qin Zhao, Fang-jiao Zhou, Xian-le Duan, Ai-ying Huang, Zheng-rui Xiang, Yu-han Zhao, Xiao Ding, & Xiao-jiang Hao (2026). A natural small molecule Hdj-15 coordinates the ER and lysosomes to induce ferroptosis by targeting TrxR1. Acta Pharmacologica Sinica. https://doi.org/10.1038/s41401-026-01938-y
Yue-qin Zhao, et al. “A natural small molecule Hdj-15 coordinates the ER and lysosomes to induce ferroptosis by targeting TrxR1.” Acta Pharmacologica Sinica, 2026. doi:10.1038/s41401-026-01938-y.
@article{Zhao2026,
title = {A natural small molecule Hdj-15 coordinates the ER and lysosomes to induce ferroptosis by targeting TrxR1},
author = {Zhao, Yue-qin and Zhou, Fang-jiao and Duan, Xian-le and Huang, Ai-ying and Xiang, Zheng-rui and Zhao, Yu-han and Ding, Xiao and Hao, Xiao-jiang},
journal = {Acta Pharmacologica Sinica},
year = {2026},
doi = {10.1038/s41401-026-01938-y},
url = {https://www.nature.com/articles/s41401-026-01938-y}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...